How S23 Storage, Stability and Handling Are Described in the Literature

The short version: what exists and what does not

S23 is an investigational non-steroidal selective androgen receptor modulator (SARM). It is a small synthetic molecule, not a peptide, which matters for every storage question on this page: the failure modes that dominate peptide handling (hydrolysis of amide bonds, aggregation, adsorption to glass, oxidation of methionine and cysteine residues) are peptide-chemistry problems and cannot be assumed to apply to a SARM by analogy.

The verified citation set supporting this page contains no published stability study of S23. There is no refrigerated storage trial, no accelerated-stability dataset, no measured shelf life, no freeze-thaw cycling experiment and no photodegradation profile for this compound in the material available here. The closest SARM-class publication is an analytical method paper: researchers reported the development of a multi-residue high-throughput UHPLC-MS/MS method for routine monitoring of SARM compounds in equine and bovine blood (https://pubmed.ncbi.nlm.nih.gov/32519780/). That work concerned detection in biological matrices, not storage of a raw or reconstituted research chemical.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing below is a handling instruction, a protocol, or a suggestion that any person should obtain or use this compound.

Why the distinction between "compound-specific" and "general" matters here

Storage pages for research compounds frequently borrow numbers from unrelated literature — a temperature range from a peptide monograph, a shelf-life figure from a lyophilised protein study — and present them as though they described the compound in the title. That is the single most common error in this genre. Where this page describes general principles of chemical or lyophilised-material handling, it is flagged as general background, not S23 data. Where a finding comes from a specific paper, the PubMed link sits in the same sentence as the finding.

Refrigeration: lyophilised solids versus solutions

General background — not S23-specific. In pharmaceutical handling terminology, "refrigerated" conventionally denotes roughly 2–8 °C, "controlled room temperature" a band around 20–25 °C, and "frozen" storage at or below −20 °C. These are definitional conventions from general pharmacy practice, not measurements taken on S23, and this page's verified citation set contains no study assigning any of those conditions to this compound.

Two broad principles explain why solid and dissolved material are usually discussed separately in chemistry literature. First, most degradation chemistry requires molecular mobility and, very often, water: a dry crystalline or lyophilised solid holds molecules in a low-mobility lattice with minimal free water, which slows hydrolytic and oxidative pathways relative to the same molecule dispersed in a solvent. Second, once a compound is in solution it is continuously exposed to the solvent, to dissolved oxygen, to any pH shift in the vehicle, and to whatever microbial load the solvent and container introduced. This is standard physical-chemistry reasoning, not a finding about S23, and no study here quantified it for this molecule.

The practical consequence for readers evaluating claims online is simple: any specific number attached to S23 — "stable for X months refrigerated", "Y% loss after Z weeks in solution" — does not come from the literature represented in this citation set. Where a supplier certificate of analysis or a safety data sheet states a storage condition, that is manufacturer documentation rather than a peer-reviewed stability study, and the two should not be described interchangeably.

Shelf life and expiry: why no figure appears on this page

A shelf-life figure is an experimental output. It comes from placing a defined batch at defined temperature and humidity conditions, sampling at intervals, and quantifying remaining parent compound and emerging degradants by a validated assay. No such experiment on S23 appears in the verified set. Stating a month count here would be an invention, so none is stated.

What the set does show is that validated quantification methods for this compound class exist in a regulatory and residue-monitoring context: the study describing a multi-residue high-throughput UHPLC-MS/MS approach was built for routine monitoring of SARM compounds in equine and bovine blood (https://pubmed.ncbi.nlm.nih.gov/32519780/). Analytical capability of that kind is the precondition for stability work, but the paper itself did not report shelf-life testing of S23 material.

Room temperature and transport conditions

General background — not S23-specific. Ambient storage and shipping introduce three variables that stability scientists track separately: temperature excursions, humidity, and light. Elevated temperature accelerates essentially all chemical degradation routes; humidity matters most for hygroscopic solids because absorbed water restores molecular mobility and provides a hydrolysis substrate; light matters for chromophore-containing molecules that can undergo photolytic cleavage.

Degradation under ambient conditions has been studied rigorously in entirely different fields, and one example in this citation set illustrates the methodology rather than the compound: researchers reported fungal biodegradation of a commercial poly(butylene adipate-co-terephthalate)–polylactic acid–thermoplastic starch bio-plastic film at ambient conditions (https://pubmed.ncbi.nlm.nih.gov/38430940/). That is a materials-science and environmental-microbiology study of a plastic film; it has no bearing on how an S23 sample behaves in a courier package, and it is cited here only to show what an ambient-conditions degradation experiment looks like when one is actually performed.

Freezing and freeze-thaw cycling

General background — not S23-specific. Freezing is generally discussed as a way to further suppress molecular mobility, but the literature on frozen storage also documents trade-offs that are compound-dependent: ice formation concentrates solutes in the remaining unfrozen liquid, pH can shift as buffer components crystallise at different rates, and repeated freeze-thaw cycles expose material to the transition zone many times over. For proteins and peptides these effects are well characterised; for a small-molecule SARM they would have to be measured directly. No freeze-thaw experiment on S23 appears in this citation set, so no cycle count, temperature or recovery percentage is stated.

Signs of degradation and how degradation is actually characterised

Visual inspection is the crudest degradation check and the least informative. Colour change, clumping or caking of a solid, particulate matter or cloudiness in a solution, and unexpected residue are the kinds of observation that laboratories record, but a compound can degrade substantially with no visible change at all — which is why analytical methods, not appearance, define stability.

What serious degradation characterisation looks like is visible in an unrelated paper in this set: the study reported that substituent structure variances altered the degradation pathways of sulfonamides in a UV/peracetic acid system, with conclusions drawn from identified intermediates, reactive oxygen species and density functional theory calculations (https://pubmed.ncbi.nlm.nih.gov/39673945/). Sulfonamides are not SARMs and a UV/PAA advanced-oxidation reactor is not a storage vial, but the design is instructive: researchers identified the breakdown products, mapped the reactive species responsible, and modelled why one structural variant degraded differently from another. Nothing equivalent has been published for S23 in the material available here, which is precisely why no degradation-marker list for this compound can be given.

Safety and Toxicology: What Studies Report

This page's verified citation set contains no human or animal toxicology data for the SARM S23, and no adverse-event dataset; the only SARM-class paper present described an analytical detection method in equine and bovine blood (https://pubmed.ncbi.nlm.nih.gov/32519780/). No dose, exposure duration, endpoint or adverse effect for S23 is reported anywhere in this set, so none is stated on this page.

Readers should also be aware that the string "S23" collides with unrelated biomedical nomenclature, which inflates the apparent literature on this compound. Two examples sit in this very citation set and concern mitochondrial ribosomal proteins rather than the SARM: one study reported that arginine and lysine methylation of MRPS23 promoted breast cancer metastasis through regulation of OXPHOS (https://pubmed.ncbi.nlm.nih.gov/33927350/), and another reported that co-targeting MRPS7-23 synergistically enhanced cisplatin efficacy against nasopharyngeal carcinoma growth and metastasis (https://pubmed.ncbi.nlm.nih.gov/41522354/). Neither study involved the selective androgen receptor modulator S23, and neither carries any implication for its storage, stability or safety.

Regulatory framing

S23 is not an approved medicine in the United States or the European Union. Material described as S23 is generally labelled for research use only, which means it has not been manufactured, tested or released under the controls that apply to approved drug products — including the stability programmes that generate expiry dating. Selective androgen receptor modulators as a class are prohibited in sport under anti-doping rules, which is one reason residue-monitoring methods such as the UHPLC-MS/MS approach for SARM compounds in equine and bovine blood were developed (https://pubmed.ncbi.nlm.nih.gov/32519780/).

Related reading

• S23: what the literature covers
• Peptide storage and stability: the general science

References

• Development of a multi-residue high-throughput UHPLC-MS/MS method for routine monitoring of SARM compounds in equine and bovine blood (Drug Testing and Analysis, 2020)
• Substituent structure variances alter degradation pathways of sulfonamides in UV/PAA system: Insights from intermediates, ROS, and DFT calculations (Journal of Hazardous Materials, 2025)
• Fungal biodegradation of poly(butylene adipate-co-terephthalate)-polylactic acid-thermoplastic starch based commercial bio-plastic film at ambient conditions (Chemosphere, 2024)
• Arginine and lysine methylation of MRPS23 promotes breast cancer metastasis through regulating OXPHOS (Oncogene, 2021)
• Co-targeting MRPS7-23 synergistically enhances cisplatin efficacy to suppress nasopharyngeal carcinoma growth and metastasis (International Journal of Biological Sciences, 2026)